

Multi-Arm Multi-Stage Trials: Developing the R package MAMS

Nikita Mozgunov¹, Dominique-Laurent Couturier¹, Michael Grayling², Dominic Magirr³, Philip Pallmann⁴, Thomas Jaki^{1,5}

¹ University of Cambridge, ² The Janssen Pharmaceutical Companies of Johnson & Johnson, ³ Novartis Pharma AG ⁴ Cardiff University, ⁵ University of Regensburg
nikita.mozgunov@mrc-bsu.cam.ac.uk <https://cran.r-project.org/package=MAMS>

INTRODUCTION

Multi-Arm Multi-Stage (MAMS) trials are innovative designs that allow the comparison of multiple treatments against a common control across several stages. These trials incorporate adaptations such as stopping for futility or efficacy at either the arm or trial level, enhancing efficiency in identifying promising interventions. Despite the existence of some specialised MAMS software, these tools are often limited in scope and usability. Our project addresses this gap by developing the MAMS R package, which is designed to be flexible, user-friendly, and accessible to users with minimal programming experience.

METHODS

The MAMS R package employs a modular approach, enabling easy integration of various methods for trial adaptation. Currently, the package implements three key methods: Simultaneous stopping, Drop-the-losers design, and separate stopping rule for platform trials.

The modular design ensures that new methods can be seamlessly incorporated into the package as they are developed. This approach enhances the package's adaptability and broadens its applicability to a wide range of MAMS (platform) trial designs.

STRUCTURE

Main MAMS package function

`mams(method = "module_name", ...)`

method =
"simultaneous"

Simultaneous
stopping rules


method =
"dtl"

Drop the losers

method =
"sep"

Separate stopping
rules

MAMS module



EXAMPLE APPLICATION

R call: `> mams(method = "dtl")`

Design	Function call	Description
Investigation of 4 experimental treatments in 2 stages with normal endpoints.	K = 4 J = 2	Number of experimental treatments Number of stages
One-sided familywise error rate of 0.05 and desired power of 0.9.	alpha = 0.05 power = 0.9	One-sided familywise error rate Desired power
Allocation ratios: r = 1:2 for experimental treatments,	r = 1:2	Vector of allocation ratios
r0 = 1:2 for control.	r0 = 1:2	Vector ratio on control
Effect size parameters	p = 0.75	Interesting treatment effect on probability scale
	p0 = 0.5	Uninteresting treatment effect on probability scale
	delta = NULL	Interesting treatment effect on traditional scale
	delta0 = NULL	Uninteresting treatment effect on traditional scale
Fixed lower boundary with shape "obf" for upper boundary.	sd = NULL	Standard deviation
	ushape = obf	Shape of upper boundary
	lshape = fixed	Shape of lower boundary
	ufix = NULL	Fixed upper boundary
Sample Size and Computational Settings	lfix = 0	Fixed lower boundary
	nstart = 1	Starting point for sample size
	nstop = NULL	Stopping point for sample size
	sample.size = TRUE	Find sample size
Simulations using 50,000 iterations, considering H0 = True.	Q = 20	Number of quadrature points
	nsim = 50000	Number of simulations
	H0 = TRUE	Consider case with all effect sizes set to 0

OUTPUT

-- MAMS design -----
-- Design characteristics --

* Normally distributed endpoint
* Drop the losers
* 2 stages
* 4 treatment arms
* 5% overall type I error
* 90% power of detecting Treatment 1 as the best arm
* Assumed effect sizes per treatment arm:

		Under H1		Under H0	
	abbr	cohen.d	prob.scale	cohen.d	prob.scale
Treatment 1	T1	0.954	0.75	0	0.5
Treatment 2	T2	0.000	0.50	0	0.5
Treatment 3	T3	0.000	0.50	0	0.5
Treatment 4	T4	0.000	0.50	0	0.5

-- Arms allocation per stage --

	Stage 1	Stage 2
Control	1	1
Treatment	4	1

-- Limits --

	Stage 1	Stage 2	shape
Upper bounds	NA	2.055	dtl
Lower bounds	NA	2.055	dtl

-- Sample sizes --

	Cumulative		Expected (\$)			Under H0		
	Stage 1	Stage 2	low	mid	high	low	mid	high
Control	13	26	26	26.000	26	26	26.000	26
Treatment 1	13	26	26	25.735	26	13	16.300	26
Treatment 2	13	26	13	13.083	13	13	16.263	26
Treatment 3	13	26	13	13.093	13	13	16.214	26
Treatment 4	13	26	13	13.090	13	13	16.223	26
TOTAL†	65	91	91.000			91.000		

† Max cumulative size per arm

‡ Based on arms allocation at each stage

-- Futility cumulated probabilities (\$) --

	Under H1		Under H0	
	Stage 1	Stage 2	Stage 1	Stage 2
Treatment 1	0	0.077	0	0.241
Treatment 2	0	0.005	0	0.238
Treatment 3	0	0.006	0	0.235
Treatment 4	0	0.006	0	0.236
ANY	0	0.095	0	0.950
ALL	0	0.000	0	0.000

-- Efficacy cumulated probabilities (\$) --

	Under H1		Under H0	
	Stage 1	Stage 2	Stage 1	Stage 2
Treatment 1	0	0.902	0	0.013
Treatment 2	0	0.001	0	0.013
Treatment 3	0	0.001	0	0.012
Treatment 4	0	0.001	0	0.012
ANY	0	0.905	0	0.050
T1 IS BEST	0	0.902	0	0.013
ALL	0	0.000	0	0.000

* Estimated T1 related power (\$) = 90.218%, [89.956, 90.478] 95% CI
* Estimated overall type I error (\$) = 5.012%, [4.822, 5.204] 95% CI

(\$) Operating characteristics estimated by a simulation considering 50000 Monte Carlo samples

REFERENCES

Jaki, T., Pallmann, P., & Magirr, D. (2019). The R Package MAMS for Designing Multi-Arm Multi-Stage Clinical Trials. *Journal of Statistical Software*, 88(4), 1–25. doi: 10.18637/jss.v088.i04
Wason J, Stallard N, Bowden J, Jennison C. A multi-stage drop-the-losers design for multi-arm clinical trials. *Statistical Methods in Medical Research*. 2017;26(1):508-524. doi:10.1177/0962280214550759

Download this poster

